Brief: Matinas Biopharma Announces Infectious Diseases Society Of America (Idsa) Has Selected The Enact Phase 2 Trial Abstract Of Mat2203 As Its Outstanding Abstract And Idsa Awardee For Idweek 2022
19/10/2022 12:34
Oct 19 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES INFECTIOUS DISEASES SOCIETY OF
AMERICA (IDSA) HAS SELECTED THE ENACT PHASE 2 TRIAL ABSTRACT OF
MAT2203 AS ITS OUTSTANDING ABSTRACT AND IDSA AWARDEE FOR IDWEEK
2022
Source text for Eikon: ID:nGNX4jYBTH
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing